Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ESSA

Patients with chronic health woes plea for end to tax

Calls are ramping up for the end of a niche health service's status as the only Medicare-backed profession to put a GST on patients.

AAP · Aug 19

RIP Sora and Claris? New drop bar Cues amalgamates Shimano's lower tiers into one family

Common shifters and new cranksets give Shimano a path to retire Tiagra, Sora and Claris

Cycling News · Jan 30, 2025

Friday roundup: Oakley hopes to make integrated visors cool, Hunt's new wallet-friendly wheels, and a new groupset from Shimano

Aero helmets are getting crazier, but will integrated visors really catch on?

Cycling Weekly · Apr 5, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Following the cue from Cues, Shimano's new Essa groupset brings big benefits to its 8-speed lineup designed for budget MTBs

New 8-speed components bring Linkglide, 1x, and wide-range cassettes to Shimano's entry-level systems. Plus small hands benefit from a new Cues short-reach shifter and brake lever

Bike Perfect · Apr 2, 2024

HUD Investigates HSBC's U.S. Unit Over Redlining Allegations

Action prompted by a non-profit’s complaint to the agency involving six metro areas.

Kiplinger · Aug 7, 2023

EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga · Jul 11, 2022

ESSA Bancorp's Ex-Dividend Date Is Wednesday, Here's What You Need To Know

Tuesday marks the last chance for investors to receive the next dividend payout from ESSA Bancorp (NASDAQ:ESSA).

Benzinga · Jun 10, 2022

Read news from The Economist, FT, and more,
with one subscription

EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga · May 27, 2022

EPIX: Preclinical Data on Androgen Receptor N-Terminal Domain Degrader Presented at AACR…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga · Apr 30, 2022

EPIX: First Patient Dosed in Combination Trial of EPI-7386 and Enzalutamide…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga · Feb 4, 2022

ESSA Pharma Announces First Patient Dosed In Phase 1/2 Clinical Trial Of EPI-7386 In Combination With Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer

ESSA Pharma Inc.

Benzinga · Jan 19, 2022

Coverage From

People

David Bautz

41 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.